C-RFCNZSCAN4, telomere elongation, mRNA
0-100 chain-logic scale · 15 dimensions · scored on public evidence
Deliver large RNA payloads for therapeutic applications, including full-length dystrophin for Duchenne muscular dystrophy.
mRNA delivery platform described as capable of large-payload delivery.
Listed by the company as a platform supporting Duchenne muscular dystrophy and other undisclosed programs.
Treat Duchenne muscular dystrophy by delivering full-length dystrophin.
Uses the Bobcat mRNA platform for large-payload mRNA delivery.
Identified in the company pipeline/site description as an application of Bobcat mRNA technology.
Treat bone marrow failure in patients with telomere biology disorders by elongating telomeres in autologous hematopoietic stem cells.
Autologous CD34+ hematopoietic stem cells exposed ex vivo to a temperature-sensitive Sendai virus vector encoding human ZSCAN4, then infused without preconditioning in a Phase I/II open-label single-center study.
Phase I/II study NCT04211714 reported early clinical experience; long-term rollover follow-up study NCT05868499 is listed for participants from protocol EXG-US-01.
In the reported clinical study, four patients were enrolled, two received EXG34217 infusion, ex vivo telomere elongation of 1.06- to 1.34-fold was observed in CD34+ cells, and no acute safety issues were noted after infusion; conclusions were limited by the small treated sample.
Evaluate a controllable self-replicating RNA vaccine against SARS-CoV-2.
Two-dose intradermal controllable self-replicating RNA vaccine encoding the SARS-CoV-2 receptor-binding domain, administered without lipid nanoparticles in a double-blind placebo-controlled Phase I/II trial.
Phase I/II clinical trial results were published in 2023 with 12-month follow-up.
No safety concerns were observed. Antibody and neutralizing antibody titers were not elevated, but antigen-specific cellular immunity was observed in the higher-dose cohort, with evidence suggesting a priming effect on later approved mRNA vaccine cellular responses.
Enable intradermal RNA vaccines that function at skin temperature and are inactivated at core body temperature as a safety switch, with a focus on cellular immunity.
Self-replicating RNA optimized around 33°C and inactivated at or above 37°C, delivered intradermally without lipid nanoparticles; tested in SARS-CoV-2 and pan-coronavirus vaccine designs.
Preclinical and translational vaccine platform findings were published in 2023.
The platform elicited predominantly cellular immunity with little or no antibody production in the described SARS-CoV-2 vaccine setting; subsequent antigen stimulation could produce antigen-specific antibodies in mice.